Last reviewed · How we verify
Propofol reduction
At a glance
| Generic name | Propofol reduction |
|---|---|
| Sponsor | University of Salamanca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Hypotension
- Nausea
- Vasoactive drug need
- Vomiting
- Tachycardia
- Bradycardia
- Chills
- Gastrooesophageal reflux disease
- Oropharyngeal pain
- Hyperhidrosis
- Respiratory distress
Key clinical trials
- EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and Sedatives (NA)
- Target-controlled Infusion With Propofol in the Emergency Department : a Prospective Study on 45 Adult Patients (PHASE4)
- Supraglottic Jet Oxygenation Ventilation During Hysteroscopic Surgery (NA)
- Reduction of Muscle Catabolism Through Brain Activation in Burn Patients (NA)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery (PHASE4)
- Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain (NA)
- Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propofol reduction CI brief — competitive landscape report
- Propofol reduction updates RSS · CI watch RSS
- University of Salamanca portfolio CI